Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT

Table 2 Baseline PRO scores

AM morning, BP Bodily Pain, CI confidence interval, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, GH General Health, HAQ-DI Health Assessment Questionnaire-Disability Index, LSM least squares mean, MCS mental component summary, MH Mental Health, PBO placebo, PCS physical component summary, PF Physical Functioning, PRO patient-reported outcome, PtGA Patient’s Global Assessment of Disease Activity, RA-WIS Work Instability Scale for RA, RE Role-Emotional, RP Role-Physical, SD standard deviation, SF Social Functioning, SF-36 Short Form 36 Health Survey, UPA upadacitinib, VAS visual analogue scale, VT Vitality
^aThe baseline values and LSM changes for SF-36 domains were transformed based on the mean and standard deviation of the 1998 general US population
^bAssessed on a numeric scale of 1 to 10, with 10 being the worst level
^cCalculated only for employed patients

ISSN: 1478-6362